Concerto Biosciences Announces Positive Topline Results from Phase 1b Clinical Trial of ENS-002 in Patients with Atopic Dermatitis
Golden Seeds company, Concerto Biosciences, a clinical-stage biotech company developing microbial products for therapeutics and consumer markets, today announced positive topline results from its first-in-human Phase 1b clinical trial evaluating ENS-002, a topical three-strain live biotherapeutic product for mild-to-moderate atopic dermatitis (AD). Read more here.

Avisi Technologies Receives FDA IDE Approval to Initiate U.S. Clinical Trial for VisiPlate Glaucoma Treatment
Golden Seeds company, Avisi Technologies, has received Investigational Device Exemption (IDE) approval from the U.S. FDA for its glaucoma treatment device, VisiPlate. This regulatory milestone allows the company to launch the SAPPHIRE clinical trial, which will evaluate VisiPlate’s safety and efficacy in patients with open-angle glaucoma in the United States. Read more here.

Uncaged Innovations’ Elevate Named as One of Time’s Best Inventions of 2025
Golden Seeds company, Uncaged Innovations, is reinventing plant-based leather alternatives by starting with the very foundation of animal leather: collagen. The result is Elevate, a material made with plant proteins from grains like wheat, soy, rice, and other agricultural byproducts that mimic collagen’s fibril structure; it looks, feels, and performs like traditional leather while “emitting 95% fewer greenhouse gases, using 89% less water, and 71% less energy” to make. Read more here.

Kind Designs Living Seawalls Named as One of Time’s Best Inventions of 2025
Golden Seeds company Kind Designs’ Living Seawalls are 3D-printed from a non-toxic concrete mixture, and can be custom-shaped to suit local flora and fauna: mangrove roots in Miami, barnacles and seagrass in New York. Their richly textured surfaces dissipate waves while providing habitats for sea life. Read more here.

Osteoboost Named as One of Time’s Best Inventions of 2025
Osteoporosis weakens bones as we age, affecting 50 million Americans, and women disproportionately. Golden Seeds company, Osteoboost, was inspired by technology used to provide the mechanical loading for astronauts to stay healthy in space. The FDA-cleared vibrating belt worn around the hips consistently reduced spinal bone loss in study participants by 85%. Read more here.

National Kidney Foundation’s Innovation Fund Invests in BMI OrganBank to Advance Breakthrough Kidney Transplant Technology
The National Kidney Foundation announced that its Innovation Fund has invested in BMI OrganBank, a medical device company pioneering next-generation organ preservation and assessment technologies. The funding will help finalize preparations for BMI OrganBank’s clinical study of its room temperature machine perfusion platform, to improve kidney transplant outcomes and reduce waitlist times for patients. Read more here.

Grasshopper Bank’s MCP: The Next Generation Of Digital Banking
Grasshopper Bank launched a first-of-its-kind Model Context Protocol (MCP) server that will enable its business banking clients to get personalized financial analysis and insights through Claude, Anthropic’s generative AI platform. While Claude is the first integration, the infrastructure sets the stage for future connectivity with other large language models (LLMs). Read more here.

Nullspace Raises $2.5M Seed Round to Enable Next-Generation Simulation Software for Radio Frequency (RF) and Quantum Applications
Golden Seeds company, Nullspace, a deep tech company developing breakthrough electromagnetic simulation software, announced a $2.5 million seed round led by Fathom Fund, with participation from Golden Seeds LLC and other strategic angel investors. Read more here.